Cancer Research Prevention Award Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kobayashi, H.
Right arrow Articles by Celis, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobayashi, H.
Right arrow Articles by Celis, E.
[Cancer Research 60, 5228-5236, September 15, 2000]
© 2000 American Association for Cancer Research

Immunology

Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2/neu Tumor Antigen1

Hiroya Kobayashi, Monique Wood, Yongsheng Song, Ettore Appella and Esteban Celis2

Department of Immunology and Cancer Center, Mayo Clinic and Mayo Graduate School, Rochester, Minnesota 55905 [H. K., M. W., E. C.], and the National Cancer Institute, NIH, Bethesda, Maryland 20892 [Y. S., E. A.]

It is accepted that both helper and CTLs play a critical role in immune antitumor responses. Thus, the design of effective immune-based therapies for cancer relies in the identification of relevant tumor-associated antigens (TAAs) capable of eliciting strong helper and cytotoxic T-cell responses against tumor cells. The product of the HER2/neu oncogene is considered as a prototype TAA, because it is found overexpressed in a large variety of malignancies, whereas normal cells only produce low levels of this product. Several cytotoxic T-cell epitopes for HER2/neu have been identified that enable the design of peptide-based therapeutic vaccines for tumors expressing this TAA. Nevertheless, it is expected that inclusion of peptide epitopes capable of eliciting HER2/neu-specific T helper responses into these vaccines may enhance their effectiveness in the clinic. We describe here a strategy to identify helper T-cell epitopes for HER2/neu that focuses on peptides predicted to bind to numerous histocompatibility alleles (promiscuous epitopes), which would encourage their use in therapeutic vaccines for the general cancer patient population. Following this approach, we successfully identified several peptides that elicited T helper (CD4+) proliferative responses to peptides derived from HER2/neu. Most of the T-cell responses appeared to reflect a low affinity for antigen, which could be the result of immune tolerance because HER2/neu is expressed in low levels in normal cells and possibly including lymphocytes and monocytes. Interestingly, one of these peptides, HER2883, was recognized by T cells in the context of either HLA-DR1, HLA-DR4, HLA-DR52, and HLA-DR53, indicating a high degree of histocompatibility promiscuity. Furthermore, T cells that reacted with peptide HER2883 could also recognize antigen-presenting cells that process HER2/neu recombinant protein. These results may be relevant for the design of more effective therapeutic vaccines for tumors expressing the HER2/neu oncogene product.




This article has been cited by other articles:


Home page
 CVIHome page
S. Gaseitsiwe, D. Valentini, R. Ahmed, S. Mahdavifar, I. Magalhaes, J. Zerweck, M. Schutkowski, E. Gautherot, F. Montero, A. Ehrnst, et al.
Major Histocompatibility Complex Class II Molecule-Human Immunodeficiency Virus Peptide Analysis Using a Microarray Chip
Clin. Vaccine Immunol., April 1, 2009; 16(4): 567 - 573.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kobayashi, T. Nagato, M. Takahara, K. Sato, S. Kimura, N. Aoki, M. Azumi, M. Tateno, Y. Harabuchi, and E. Celis
Induction of EBV-Latent Membrane Protein 1-Specific MHC Class II-Restricted T-Cell Responses against Natural Killer Lymphoma Cells
Cancer Res., February 1, 2008; 68(3): 901 - 908.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kobayashi, T. Nagato, K. Sato, N. Aoki, S. Kimura, M. Murakami, H. Iizuka, M. Azumi, H. Kakizaki, M. Tateno, et al.
Recognition of Prostate and Melanoma Tumor Cells by Six-Transmembrane Epithelial Antigen of Prostate-Specific Helper T Lymphocytes in a Human Leukocyte Antigen Class II-Restricted Manner
Cancer Res., June 1, 2007; 67(11): 5498 - 5504.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Nagato, H. Kobayashi, M. Yanai, K. Sato, N. Aoki, K. Oikawa, S. Kimura, Y. Abe, E. Celis, Y. Harabuchi, et al.
Functional Analysis of Birch Pollen Allergen Bet v 1-Specific Regulatory T Cells
J. Immunol., January 15, 2007; 178(2): 1189 - 1198.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, T. Ngato, K. Sato, N. Aoki, S. Kimura, Y. Tanaka, H. Aizawa, M. Tateno, and E. Celis
In vitro Peptide Immunization of Target Tax Protein Human T-Cell Leukemia Virus Type 1-Specific CD4+ Helper T Lymphocytes.
Clin. Cancer Res., June 15, 2006; 12(12): 3814 - 3822.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
C. T. Viehl, M. Becker-Hapak, J. S. Lewis, Y. Tanaka, U. K. Liyanage, D. C. Linehan, T. J. Eberlein, and P. S. Goedegebuure
A Tat Fusion Protein-Based Tumor Vaccine for Breast Cancer
Ann. Surg. Oncol., July 1, 2005; 12(7): 517 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Rodeberg, R. A. Nuss, S. F. Elsawa, and E. Celis
Recognition of Six-Transmembrane Epithelial Antigen of the Prostate-Expressing Tumor Cells by Peptide Antigen-Induced Cytotoxic T Lymphocytes
Clin. Cancer Res., June 15, 2005; 11(12): 4545 - 4552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, T. Nagato, K. Oikawa, K. Sato, S. Kimura, N. Aoki, R. Omiya, M. Tateno, and E. Celis
Recognition of Prostate and Breast Tumor Cells by Helper T Lymphocytes Specific for a Prostate and Breast Tumor-Associated Antigen, TARP
Clin. Cancer Res., May 15, 2005; 11(10): 3869 - 3878.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Takeuchi, S.-i. Hiraoka, X.-Y. Zhou, M. Nagafuku, S. Ono, T. Tsujimura, M. Nakazawa, Y. Yura, T. Hamaoka, and H. Fujiwara
Anti-HER-2/neu Immune Responses Are Induced before the Development of Clinical Tumors but Declined following Tumorigenesis in HER-2/neu Transgenic Mice
Cancer Res., October 15, 2004; 64(20): 7588 - 7595.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, T. Nagato, M. Yanai, K. Oikawa, K. Sato, S. Kimura, M. Tateno, R. Omiya, and E. Celis
Recognition of Adult T-Cell Leukemia/Lymphoma Cells by CD4+ Helper T Lymphocytes Specific for Human T-Cell Leukemia Virus Type I Envelope Protein
Clin. Cancer Res., October 15, 2004; 10(20): 7053 - 7062.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ruiz, H. Kobayashi, J. J. Lasarte, J. Prieto, F. Borras-Cuesta, E. Celis, and P. Sarobe
Identification and Characterization of a T-Helper Peptide from Carcinoembryonic Antigen
Clin. Cancer Res., April 15, 2004; 10(8): 2860 - 2867.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. S. Schultz, B. Schuler-Thurner, V. Stroobant, L. Jenne, T. G. Berger, K. Thielemanns, P. van der Bruggen, and G. Schuler
Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy
J. Immunol., January 15, 2004; 172(2): 1304 - 1310.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Piechocki, Y.-S. Ho, S. Pilon, and W.-Z. Wei
Human ErbB-2 (Her-2) Transgenic Mice: A Model System for Testing Her-2 Based Vaccines
J. Immunol., December 1, 2003; 171(11): 5787 - 5794.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Teramoto, K. Kontani, Y. Ozaki, S. Sawai, N. Tezuka, T. Nagata, S. Fujino, Y. Itoh, O. Taguchi, Y. Koide, et al.
Deoxyribonucleic Acid (DNA) Encoding a Pan-Major Histocompatibility Complex Class II Peptide Analogue Augmented Antigen-specific Cellular Immunity and Suppressive Effects on Tumor Growth Elicited by DNA Vaccine Immunotherapy
Cancer Res., November 15, 2003; 63(22): 7920 - 7925.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, R. Omiya, B. Sodey, M. Yanai, K. Oikawa, K. Sato, S. Kimura, S. Senju, Y. Nishimura, M. Tateno, et al.
Identification of Naturally Processed Helper T-Cell Epitopes from Prostate-Specific Membrane Antigen Using Peptide-Based in Vitro Stimulation
Clin. Cancer Res., November 1, 2003; 9(14): 5386 - 5393.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Mandic, C. Almunia, S. Vicel, D. Gillet, B. Janjic, K. Coval, B. Maillere, J. M. Kirkwood, and H. M. Zarour
The Alternative Open Reading Frame of LAGE-1 Gives Rise to Multiple Promiscuous HLA-DR-restricted Epitopes Recognized by T-helper 1-type Tumor-reactive CD4+ T Cells
Cancer Res., October 1, 2003; 63(19): 6506 - 6515.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Bonehill, C. Heirman, S. Tuyaerts, A. Michiels, Y. Zhang, P. van der Bruggen, and K. Thielemans
Efficient Presentation of Known HLA Class II-restricted MAGE-A3 Epitopes by Dendritic Cells Electroporated with Messenger RNA Encoding an Invariant Chain with Genetic Exchange of Class II-associated Invariant Chain Peptide
Cancer Res., September 1, 2003; 63(17): 5587 - 5594.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Schroers, L. Shen, L. Rollins, Z. Xiao, G. Sonderstrup, K. Slawin, X. F. Huang, and S.-Y. Chen
Identification of MHC Class II-restricted T-cell Epitopes in Prostate-specific Membrane Antigen
Clin. Cancer Res., August 1, 2003; 9(9): 3260 - 3271.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Davila, R. Kennedy, and E. Celis
Generation of Antitumor Immunity by Cytotoxic T Lymphocyte Epitope Peptide Vaccination, CpG-oligodeoxynucleotide Adjuvant, and CTLA-4 Blockade
Cancer Res., June 15, 2003; 63(12): 3281 - 3288.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Tanaka, S. F. Dowdy, D. C. Linehan, T. J. Eberlein, and P. S. Goedegebuure
Induction of Antigen-Specific CTL by Recombinant HIV Trans-Activating Fusion Protein-Pulsed Human Monocyte-Derived Dendritic Cells
J. Immunol., February 1, 2003; 170(3): 1291 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Lu, R. L. Giuntoli II, R. Omiya, H. Kobayashi, R. Kennedy, and E. Celis
Interleukin 15 Promotes Antigen-independent in Vitro Expansion and Long-Term Survival of Antitumor Cytotoxic T Lymphocytes
Clin. Cancer Res., December 1, 2002; 8(12): 3877 - 3884.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, R. Omiya, M. Ruiz, E. Huarte, P. Sarobe, J. J. Lasarte, M. Herraiz, B. Sangro, J. Prieto, F. Borras-Cuesta, et al.
Identification of an Antigenic Epitope for Helper T Lymphocytes from Carcinoembryonic Antigen
Clin. Cancer Res., October 1, 2002; 8(10): 3219 - 3225.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Omiya, C. Buteau, H. Kobayashi, C. V. Paya, and E. Celis
Inhibition of EBV-Induced Lymphoproliferation by CD4+ T Cells Specific for an MHC Class II Promiscuous Epitope
J. Immunol., August 15, 2002; 169(4): 2172 - 2179.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
I. Caro-Aguilar, A. Rodriguez, J. M. Calvo-Calle, F. Guzman, P. De la Vega, M. Elkin Patarroyo, M. R. Galinski, and A. Moreno
Plasmodium vivax Promiscuous T-Helper Epitopes Defined and Evaluated as Linear Peptide Chimera Immunogens
Infect. Immun., July 1, 2002; 70(7): 3479 - 3492.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
C. Buteau, S. N. Markovic, and E. Celis
Challenges in the Development of Effective Peptide Vaccines for Cancer
Mayo Clin. Proc., April 1, 2002; 77(4): 339 - 349.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
H. M. Zarour, B. Maillere, V. Brusic, K. Coval, E. Williams, S. Pouvelle-Moratille, F. Castelli, S. Land, J. Bennouna, T. Logan, et al.
NY-ESO-1 119-143 Is a Promiscuous Major Histocompatibility Complex Class II T-Helper Epitope Recognized by Th1- and Th2-Type Tumor-reactive CD4+ T Cells
Cancer Res., January 1, 2002; 62(1): 213 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kobayashi, J. Lu, and E. Celis
Identification of Helper T-Cell Epitopes That Encompass or Lie Proximal to Cytotoxic T-Cell Epitopes in the gp100 Melanoma Tumor Antigen
Cancer Res., October 1, 2001; 61(20): 7577 - 7584.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Piechocki, S. A. Pilon, and W.-Z. Wei
Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2
J. Immunol., September 15, 2001; 167(6): 3367 - 3374.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kobayashi, Y. Song, D. S. B. Hoon, E. Appella, and E. Celis
Tumor-reactive T Helper Lymphocytes Recognize a Promiscuous MAGE-A3 Epitope Presented by Various Major Histocompatibility Complex Class II Alleles
Cancer Res., June 1, 2001; 61(12): 4773 - 4778.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.